SOURCE: Atossa Genetics, Inc.

Atossa Genetics, Inc.

September 23, 2013 08:30 ET

Atossa Genetics to Conduct Free Webinar: How to Invest Ahead of Breast Cancer Awareness Month

SEATTLE, WA--(Marketwired - Sep 23, 2013) -  Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, today announced that Dr. Steven C. Quay, Chairman, President & CEO, will conduct a free webinar via The Money Show, titled, "How to Invest Ahead of Breast Cancer Awareness Month." The webinar will take place on Wednesday, September 25, from 4:30-5:30 pm Eastern Time. Investors interested in registering for this webinar should visit: and click on REGISTER FREE.

Dr. Quay stated, "October will be our first Breast Cancer Awareness Month as a public company. This free webinar will provide investors with an opportunity to learn about Atossa's unique business approach to the prevention of breast cancer through its patented medical devices and laboratory testing services, including the ForeCYTE Breast Health Test for breast cancer risk assessment."

About the ForeCYTE Breast Health Test

The ForeCYTE Breast Health Test, intended for the 110 million women in the U.S. ages 18 to 73, is a painless, quick and non-invasive procedure that can be done in a physician's office. The test specimens are then analyzed at Atossa's laboratory, The National Reference Laboratory for Breast Health, Inc. (NRLBH), which can provide vital early detection of cancer or pre-cancerous conditions that may progress to cancer over an approximately eight-year period and before cancer can be detected by mammography or other means and without the risks of radiation, especially in women younger than age 50. No invasive biopsy needles or open surgical incisions are used in the Atossa test.

Just as the Pap smear has reduced cervical cancer rates by over 70 percent, becoming the most successful screening test in medicine, the goal of Atossa Genetics is to reduce the stubbornly high rate of breast cancer through the early detection of the precursor changes that can lead to breast cancer and the treatment of those early changes. For more information, please visit

About Atossa Genetics, Inc.

Atossa Genetics, Inc. is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and, through its wholly-owned subsidiary, The NRLBH, patented, laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography.

The NRLBH is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington.

For additional information, on Atossa and the NRLBH, please visit and For further information on the ForeCYTE Breast Health Test, please visit

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Contact Information

  • Contact:

    Atossa Genetics, Inc.
    Kyle Guse
    CFO & General Counsel
    (O) 800-351-3902
    (M) 206-678-7560
    Email Contact

    MBS Value Partners, LLC (Investors)
    Matthew D. Haines
    Managing Director
    (O) 212-710-9686
    Email Contact

    JQA Partners, LLC (media)
    Jules Abraham
    (O) 917-885-7378
    Email Contact